Objective Although previous studies suggest that treatment of dyslipidemia with statins reduces mortality and morbidity that are associated with cardiovascular disease, only a few studies have examined the efficacy of statins on atherosclerotic status in patients with chronic kidney disease (CKD). Materials and Methods A 12-month, prospective, randomized study was designed to assess the efficacy of rosuvastatin in reducing circulating atherosclerotic parameters and renal function in patients with CKD. Thirty-eight patients with CKD and LDL cholesterol levels 100 mg/dL were randomly assigned to receive 2.5 mg/dL rosuvastatin (group A, n=22) or nonrosuavastatin therapy (group B, n=16). Lipid profile, estimated glomerular filtration rate (eGFR), high sensitivity C-reactive protein (hs-CRP), and intima-media thickness (IMT) were measured before and 12 months after rosuvastatin was added to the treatment. Results Total cholesterol, low-density lipoprotein cholesterol, remnant-like particle-cholesterol and triglycerides were significantly reduced only in patients who received rosuvastatin. These parameters remained unchanged in patients who were not treated with rosuvastatin. eGFR was significantly increased from 50.7±18.7 mL/min/1.73 m 2 to 53.3±20.1 mL/min/1.73 m 2 and a significant reduction of U-P was detected in group A patients (0.17±0.29 vs. 0.13±0.3 g/day; p<0.01). In addition to the hypolipidemic effect, rosuvastatin treatment significantly reduced hs-CRP (p=0.0054). Moreover, maximal IMT at the baseline (1.89±0.98 mm) decreased significantly to 1.75±0.87 mm at 12 months (p=0.0231). Conclusion Rosuvastatin treatment, in addition to its beneficial effect on cholesterol levels, reduced maximal IMT and modified the inflammatory state of these patients.
Introduction
Patients with chronic kidney disease (CKD) have a markedly higher prevalence of cardiovascular disease (CVD) than the general population (1, 2) . They have an altered plasma lipid profile that is characterized by increased levels of triglycerides, decreased levels of high-density cholesterol (HDL)-C, and no consistent change in low-density lipoprotein cholesterol (LDL)-C (3) . Furthermore, dyslipidemia is considered a major cause of CVD in patients with CKD, and management of dyslipidemia plays an important role in the therapy of these patients (4) .
It has been established that the benefits of hepatic hydroxymethyl glutaryl-CoA reductase inhibitors, or statins, in cardiovascular disease can be explained not only by their lipid-lowering potential but also by non-lipid-related mechanisms, the so-called "pleiotropic effects". Some of these beneficial effects are related to the anti-inflammatory properties of statins, which may contribute to this positive effect of statins on the incidence of cardiovascular events (5) .
It was published recently that reducing the inflammatory T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s o f P a t i e n t s wi t h CKD a t B a s e l i n e component of cardiovascular disease through the use of statin therapy improves the clinical outcome independent of the reduction in serum cholesterol levels (6) . Although previous studies suggest that treatment of dyslipidemia with a statin reduces morbidity and mortality that are associated with CVD (7, 8) , only a few studies have examined the efficacy of statins on dyslipidemia (9) and atherosclerotic status in patients with CKD, and most of these studies were performed in patients who had end-stage renal disease (ESRD) and were on dialysis but not in nondialyzed patients. The present prospective study was designed to evaluate the inflammatory and anti-atherosclerotic responses of rosuvastatin in patients with CKD.
Materials and Methods

Study population and treatment protocol
Thirty-eight patients with CKD (stage 2 to 4) were enrolled. All received medical treatment at Department of Medicine, Kidney Center in Tokyo Women's Medical University. Written informed consent was obtained from all patients before the study. This study complies with the Declaration of Helsinki and was in agreement with the guidelines approved by the ethics committee at our institution. Inclusion criteria were CKD with an estimated GFR <90 mL/min and 15 mL/min. Exclusion criteria were levels of fasting serum LDL-C of <100 mg/dL and >200 mg/dL; the existence of liver, cardiovascular, infectious, or systemic disease unrelated to ESRD; and the history of vascular intervention, congestive heart failure, or myocardial infraction within the 3 month proceeding of the period of enrollment. No patient took lipid-lowering medication the 4-week period before the study.
Fifty CKD patients were randomly selected for this study and divided into two groups (25 patients × 2 groups). However, 3 patients in group A did not complete the study protocol and 9 patients in group B took different stains for treatment. All patients who met the eligibility criteria were randomly assigned to two groups. Group A included 22 patients who took rosuvastatin (2.5 mg/day for 12 months), and group B included 16 patients who did not take lipidlowering drugs. Patients who were already taking other drugs kept their pharmacologic schedule constant during the study. Most of patients were receiving anti-hypertensive agents including renin-angiotensin system blockers, and their dosages were not changed during rosuvastatin therapy as listed in Table 1 .
T a b l e 2 . Re n a l F u n c t i o n a n d L i p i d P a r a me t e r s i n B o t h Gr o u p s o f CKD
Measurements of lipid profile and inflammatory markers
Venous blood samples were obtained before and after 12 months of rosuvastatin treatment and stored frozen at -80 . Serum creatinine, total cholesterol (TC), HDL-C, LDL-C, and serum triglyceride (TG) levels were determined by means of standard enzymatic methods. GFR was estimated by the MDRD formula as previously described (10) . Urinary protein excretion (U-P) was determined by 24 hours. Plasma high-sensitivity C-reactive protein (hs-CRP) levels were measured with a latex-based turbidimetric immunoassay on a Hitachi analyzer (Sigma Chemical Co., St Louis, MO, USA). Fasting remnant-like particle-cholesterol (RLP-C) was also measured at the baseline and 12 months using a commercial kit (SRL Laboratory, Tokyo). Serum adiponectin (ADPN) was measured with a human ADPN ELISA kit (Otsuka Pharmaceuticals, Tokyo) as previously described (11) .
Measurement of IMT
IMT of the common carotid arteries, a validated marker of generalized atherosclerosis, was determined by ultrasonographical B-mode imaging of the carotid artery performed using a high resolution real-time ultrasonograph with a 12-MHz in-line Sectascanner (SSA-390A; Toshiba, Tokyo) (12) . For each patient, three measurements were performed on the bilateral carotid arteries and the averaged values of maximal IMT were considered for analysis. All measurements were made by the same examiner under blind conditions.
Statistical analyses
Data are expressed as means + SD. We assessed differences between baseline and 12 month values using the t test for paired data, univariate analysis for normally distributed variables and Mann-Whitney U test for skewed variables. The calculation was conducted by Stat View ver 5.0 (SAS, Cary, CA, USA) and statistical significance was assumed at p<0.05.
Results
All patients from group A and group B completed the study. Table 1 lists baseline characteristics of the patients with CKD. Primary disease was nephrosclerosis in all patients studied. There were no statistically significant differences between the two study groups at baseline evaluation, while eGFR in group A was significantly lower (50.7±18.7 mL/min/1.73 m 2 ) than those (54.9±10.6 mL/min/1.73 m 2 ) in group B (p<0.05). History of CVD was recorded 7 patients in group A and 6 in group B. However, no patients had new CVD events during the study period. No significant difference was noted in medical treatment with anti-hypertensive agents including renin-angiotensin system blockers.
Comparison of average serum lipid levels at the baseline and 12 month endpoint showed the expected variations during rosuvastatin therapy in group A patients ( Table 2) : A significant reduction in serum levels of TC (p<0.001), LDL cholesterol (p<0.001), triglycerides (p=0.002), and RLP-C (p=0.002). Conversely, no significant variations in lipid levels appeared in group B patients ( Table 2 ).
In addition to lipid-lowering effects of rosuvastatin, renal protective effects appeared in group A. eGFR was significantly increased from 50.7±18.7 mL/min/1.73 m 2 
. Ch a n g e s i n i n t i ma -me d i a t h i c k n e s s ( I MT ) i n 2 2 p a t i e n t s wh o t o o k r o s u v a s t a t i n ( A) a n d i n 1 6 p a t i e n t s wh o d i d n o t t a k e l i p i d -l o we r i n g d r u g s ( B ) .
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0.0231) (Fig. 1 ).
Discussion
Pleiotropic effects of statins have important clinical implications, independent of their lipid-lowering effects (13) . Patients with CKD, even those in the early stages of the disorder, are at increased risk for CVD, and recent reviews suggested that oxidant stress and inflammation may be the primary mediators that explain the burden of CVD in patients with CKD (14) . Although rosuvastatin reduced the incidence of cardiovascular events in patients who were on hemodialysis in a recently published large, prospective study (15) , anti-atherosclerotic effects of this statin have not been explored in patients with CKD.
Our randomized, prospective study describes the impact of rosuvastatin on atherosclerotic parameters in nondialyzed patients with CKD. Serum levels of TC, LDL-C, RLP-C and TG were significantly reduced in patients who received rosuvastatin. In addition to the hypolipidemic effect, rosuvastatin significantly reduced hs-CRP and maximal IMT, suggesting that rosuvastatin treatment, in addition to its beneficial effect on serum lipid levels, reduced atherosclerotic state in these patients.
Slowing the progression of CKD by lipid-lowering agents could indirectly lead to reduction in CVD in these patients. The contribution of dyslipidemia to progression of CKD is supported by animal studies. Two meta-analyses (16, 17) and several post hoc analyses of large international studies (7, 18) provide further evidence that statins slow decline in GFR. However, the most recent systematic review which evaluated up to 40,000 participants revealed that statins only had a modest effect on slowing decline in GFR and was significantly only in those with known CVD (17) . Two reports indicated that rosuvastatin treatment tended to preserve GFR in patients with CKD (19, 20) . Although previous reports suggest a benefit of statins in early stage CKD, similar results have not be replicated in more advanced (stages 4-5) CKD patients. This lack of efficacy in CKD may be related to delay in initiating therapy in patients who already have an atypically severe form of atherosclerosis (21) . A few recent studies described the impact of statins on serum CRP levels in patients with CKD. Panichi et al (9) described that simvastatin in commonly used dosages has in vitro and in vivo anti-inflammatory effect in patients with CKD. Recently, Goicoechea et al (22) described that atorvastatin treatments, in addition to its beneficial effect on lipid profile, improves the inflammatory state of patients with CKD without modifying fibrinolytic balance. These studies confirm the findings that patients with CKD have higher levels of inflammatory markers such as CRP than general population. As described in patients who had ESRD and were on hemodialysis therapy (23) (24) (25) , statin treatment in group A patients significantly reduced inflammatory parameters.
Adiponectin (ADPN) , the most abundant protein secreted from adipose tissue, possesses anti-atherogenic, antiinflammatory, and ant-diabetic effects (26) . It is expected that the lipid-lowering drugs may be capable of increasing serum ADPN levels. The present study clearly shows that serum ADPN levels significantly increased in CKD patients treated with rosuvastatin. The present study suggested that anti-inflammatory effects of rosuvastatin may be related to the increase in ADPN levels. Iwashima et al (27) reported that renal function is a significant regulator of ADPN when categorized by CKD stage, whereas hypoadiponectinemia is a predictor of CVD, including recurrent ischemic heart disease. It is likely that the increased ADPN levels induced by rosuvastatin are related to a reduction of atherosclerotic burden in these patients.
Study Limitations
There are several limitations such as small sample size leading to inadequate assessment, short duration of therapy, and selection of a heterogeneous group of patients with CKD. A longer duration of the therapy warrants examination because the improvement in the atherosclerotic burden.
Conclusion
In nondialysis patients with CKD, treatment with rosuvastatin (2.5 mg/day) for 12 months induced a lipid-lowering effect and a significant decrease in inflammatory parameters and IMT. Such evidence, similar to that observed in hemodialysis patients, could suggest a new therapeutic use of statins in the prevention of cardiovascular damage in patients with CKD.
